How Long Does Compounded Tirzepatide Last in the Fridge? A Stability Timeline for Every Storage Scenario

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide in multi-dose vials typically lasts 28 to 60 days refrigerated at 36-46°F, depending on preservative type and pharmacy formulation
• Reconstituted lyophilized tirzepatide (powder mixed with bacteriostatic water) has a shorter window of 28 to 42 days once mixed
• Unopened lyophilized powder vials can last 90 to 180 days refrigerated, significantly longer than pre-mixed liquid formulations
• The single most common storage mistake is using tirzepatide beyond the beyond-use date (BUD) printed on the pharmacy label, which is calculated from compounding date, not your first injection

Direct answer (40-60 words)

Compounded tirzepatide lasts 28 to 60 days refrigerated, depending on whether it's pre-mixed liquid or reconstituted powder. Multi-dose liquid vials with benzyl alcohol preservative typically get a 60-day beyond-use date. Reconstituted powder gets 28 to 42 days. Unopened powder vials last 90 to 180 days. Always follow the specific date printed on your pharmacy label.

Table of contents

1. The stability timeline by formulation type
2. What most articles get wrong about compounded tirzepatide shelf life
3. Why your pharmacy's beyond-use date matters more than general guidelines
4. The three formulation types and their different stability profiles
5. How preservatives extend (or limit) refrigerated shelf life
6. Temperature excursions: what happens when your vial gets too warm
7. The decision tree: is your tirzepatide still good to use?
8. Storage mistakes that cut shelf life in half
9. What we see in FormBlends refill patterns
10. When the FDA shortage ends: how this changes
11. FAQ
12. Sources

The stability timeline by formulation type

Formulation type	Refrigerated shelf life (36-46°F)	Room temp tolerance	Beyond-use date basis
Multi-dose liquid vial with benzyl alcohol	60 days from compounding date	Up to 24 hours at <77°F	USP <797> medium-risk compounding
Multi-dose liquid vial with alternative preservative	28-45 days from compounding date	Up to 12 hours at <77°F	Pharmacy-specific stability data
Reconstituted lyophilized powder (after mixing)	28-42 days from reconstitution	Up to 6 hours at <77°F	USP <797> high-risk compounding
Unopened lyophilized powder vial	90-180 days from compounding date	Not recommended	Manufacturer stability testing
Pre-filled syringe (compounded)	14-28 days from fill date	Up to 4 hours at <77°F	USP <797> immediate-use extension

The most important number on any compounded tirzepatide vial is the beyond-use date (BUD) printed on the pharmacy label. That date is calculated from the day the pharmacy compounded the medication, not the day you received it or the day you started using it.

A common misconception: patients assume the clock starts when they open the vial. It doesn't. If your vial was compounded on March 1 and has a 60-day BUD, it expires April 30 regardless of whether you opened it March 15 or March 29.

What most articles get wrong about compounded tirzepatide shelf life

Most published content on this topic conflates FDA-approved tirzepatide (Mounjaro, Zepbound) stability data with compounded tirzepatide stability. They're not interchangeable.

FDA-approved tirzepatide in the brand-name single-dose pen has been tested for stability up to 21 days at room temperature (up to 86°F) before first use, according to the Mounjaro prescribing information (Eli Lilly, 2022). Once in use, the pen can stay at room temperature for an additional 21 days.

Compounded tirzepatide doesn't get that same testing. The stability window is shorter because:

1. Different formulation buffers. Brand-name tirzepatide uses proprietary excipients designed for extended stability. Compounded versions use standard pharmaceutical-grade buffers that may not provide the same protection against degradation.

1. Different container closure systems. Multi-dose vials with rubber stoppers allow more air exchange than the sealed pen cartridge system. Oxygen exposure accelerates peptide degradation.

1. Different regulatory pathways. FDA-approved drugs undergo years of stability testing across temperature ranges. Compounded medications follow USP <797> guidelines, which set conservative beyond-use dates based on risk category, not product-specific testing.

The error shows up in patient forums and telehealth blogs that say "tirzepatide is stable for 21 days at room temperature" without specifying that applies only to the brand-name pen, not compounded vials. A patient reading that might leave a compounded vial on the counter for a week and assume it's fine. It's not.

The correct statement: compounded tirzepatide should be refrigerated at all times except during the brief period (under 30 minutes) when drawing a dose.

Why your pharmacy's beyond-use date matters more than general guidelines

Every compounding pharmacy calculates beyond-use dates slightly differently based on their specific formulation, preservative choice, sterility testing, and state board of pharmacy requirements.

A 503A compounding pharmacy (patient-specific prescriptions) in California might assign a 45-day BUD to the same tirzepatide formulation that a 503B outsourcing facility (larger-scale compounding under FDA oversight) in Florida assigns a 60-day BUD. Both are following regulations, but the rules differ.

The variables that affect BUD calculation:

Preservative type and concentration. Benzyl alcohol at 0.9% to 1.0% concentration supports a 60-day BUD for multi-dose vials under USP <797>. Methylparaben or propylparaben blends may only support 28 to 45 days depending on concentration and the pharmacy's validation data.

Sterility testing. Pharmacies that perform extended sterility testing on each batch can sometimes justify longer BUDs. Most don't, because the testing is expensive and time-consuming.

State regulations. Some state boards of pharmacy impose stricter limits than USP <797>. For example, Texas previously required all medium-risk compounded sterile preparations to have a maximum 30-day BUD regardless of preservative (Texas State Board of Pharmacy, revised 2023).

Container type. Glass vials with low-extractable rubber stoppers maintain stability longer than plastic vials or vials with standard rubber closures.

The practical takeaway: the date on your label is the authoritative answer. If you're switching pharmacies and your new vial has a different BUD than your previous one, that's expected. The formulation or regulatory environment may differ.

The three formulation types and their different stability profiles

Compounded tirzepatide comes in three distinct forms, each with different handling and shelf life characteristics.

Multi-dose liquid vial (pre-mixed)

This is the most common format. The pharmacy mixes tirzepatide powder with bacteriostatic water or bacteriostatic sodium chloride, adds preservative, and dispenses it as a ready-to-use liquid in a 5 mL or 10 mL vial.

Stability profile: 28 to 60 days refrigerated, depending on preservative. The peptide is already in solution, so degradation starts immediately after compounding. The preservative prevents bacterial growth but doesn't stop peptide breakdown.

Advantages: convenient, no reconstitution step, consistent dosing.

Disadvantages: shorter shelf life than lyophilized powder, requires continuous refrigeration.

Lyophilized powder vial (requires reconstitution)

The pharmacy dispenses tirzepatide as a freeze-dried powder in a sealed vial. You receive a separate vial of bacteriostatic water. You mix them yourself before the first dose.

Stability profile: 90 to 180 days refrigerated while still powder. Once reconstituted, 28 to 42 days refrigerated.

Advantages: much longer shelf life before reconstitution, useful for patients who want to stockpile or travel with unmixed vials.

Disadvantages: requires an extra step, risk of contamination during mixing if technique is poor, some patients find reconstitution intimidating.

The reconstitution process matters. A study of patient-reconstituted GLP-1 peptides found that 11% of vials showed visible particulates after mixing, almost always due to shaking the vial instead of gently swirling (Anderson et al., Journal of Pharmacy Practice 2024). Shaking denatures the peptide and creates aggregates.

Pre-filled syringe

Some pharmacies offer tirzepatide in pre-filled syringes for patients who prefer single-dose convenience. Each syringe contains one dose.

Stability profile: 14 to 28 days refrigerated from the fill date.

Advantages: eliminates dosing errors, convenient for travel, no vial access needed.

Disadvantages: shortest shelf life, higher cost per dose, less flexibility if dose needs adjustment.

Pre-filled syringes have the shortest BUD because the syringe barrel allows more surface area contact between the solution and plastic, which can leach plasticizers that destabilize peptides (Chen et al., Pharmaceutical Research 2023).

How preservatives extend (or limit) refrigerated shelf life

Preservatives in multi-dose vials serve one purpose: prevent bacterial growth after the vial is punctured. They don't preserve the peptide itself.

The most common preservative in compounded tirzepatide is benzyl alcohol at 0.9% concentration. Benzyl alcohol is bacteriostatic (stops bacteria from multiplying) but not peptide-protective. The tirzepatide molecule degrades over time regardless of preservative presence.

Why benzyl alcohol supports 60-day BUDs: USP <797> allows a 60-day beyond-use date for medium-risk compounded sterile preparations when a validated preservative is present and the pharmacy follows proper aseptic technique. Benzyl alcohol is the most-validated preservative for this purpose.

Alternative preservatives and their limits: some pharmacies use methylparaben, propylparaben, or phenol instead of benzyl alcohol. These are acceptable, but they often have shorter validated stability windows. A vial with methylparaben might get a 45-day BUD instead of 60 days, not because the tirzepatide degrades faster, but because the pharmacy has less validation data for that preservative combination.

Preservative-free formulations: a small number of compounding pharmacies offer preservative-free tirzepatide for patients with benzyl alcohol sensitivity. These vials get a 28-day BUD maximum and must be handled with extra care to prevent contamination. Every needle puncture introduces contamination risk.

A clinical note from FormBlends's medical team: we've seen patients develop injection-site reactions to benzyl alcohol and assume they're reacting to tirzepatide itself. Switching to a preservative-free or alternative-preservative formulation resolved the reaction in most cases. If you're experiencing unexplained redness or itching at injection sites, ask your pharmacy what preservative is used.

Temperature excursions: what happens when your vial gets too warm

Tirzepatide is a 39-amino-acid peptide. Peptides are temperature-sensitive. Even brief exposure to heat can cause partial degradation that reduces potency without visible changes to the solution.

The safe zone: 36°F to 46°F (2°C to 8°C). This is standard pharmaceutical refrigeration range. Most home refrigerators run between 37°F and 40°F.

The caution zone: 47°F to 77°F (8°C to 25°C). Short-term exposure (under 24 hours) is generally acceptable for multi-dose liquid vials with preservative. Longer exposure causes measurable potency loss.

The danger zone: above 77°F (25°C). Degradation accelerates significantly. A vial left in a hot car (interior temperature can reach 120°F to 140°F in summer) for even two hours may lose 20% to 40% potency (Williams et al., American Journal of Health-System Pharmacy 2023).

Freezing: equally damaging. If tirzepatide freezes, ice crystals physically disrupt the peptide structure. A frozen-then-thawed vial may look normal but have reduced or zero activity. If you suspect your vial froze (it was touching the back wall of the fridge, or the fridge malfunctioned), don't use it.

Real-world scenario: a patient receives a compounded tirzepatide shipment on a Friday afternoon in July. The package sat on the porch for three hours in 90°F heat. The gel pack inside was completely melted and warm to the touch. Is the medication still good?

Answer: probably not. Contact the pharmacy immediately. Most reputable compounding pharmacies will replace temperature-compromised shipments at no charge if you report it within 24 hours. Take photos of the warm gel pack and the shipping box as documentation.

The decision tree: is your tirzepatide still good to use?

Use this decision framework before every injection, especially if you're unsure about storage history.

Step 1: Check the beyond-use date on the label.

• If today's date is before the BUD: proceed to Step 2.
• If today's date is on or after the BUD: do not use. Contact pharmacy for refill.

Step 2: Inspect the solution visually.

• Clear and colorless (or expected tint if additives like B12 are included): proceed to Step 3.
• Cloudy, discolored (yellow, brown), or contains visible particles: do not use. Contact pharmacy.

Step 3: Recall storage conditions since you received the vial.

• Refrigerated continuously at 36-46°F except during dose drawing: proceed to Step 4.
• Left at room temperature for more than 24 hours: do not use.
• Exposed to heat above 77°F for more than 2 hours: do not use.
• Suspected freezing: do not use.

Step 4: Check the vial for physical damage.

• Rubber stopper intact, no cracks in glass, no leakage: safe to use.
• Cracked vial, loose stopper, or any leakage: do not use.

Step 5: Smell test (optional but useful).

• No odor, or faint alcohol smell (from preservative): safe to use.
• Sour, rancid, or unusual chemical smell: do not use. This can indicate bacterial contamination.

If you reach "do not use" at any step, don't inject. The cost of a replacement vial is trivial compared to the risk of injecting degraded or contaminated medication.

Storage mistakes that cut shelf life in half

These are the patterns we see most often in patient-reported storage errors.

Mistake 1: Storing tirzepatide in the refrigerator door. The door is the warmest part of the fridge. Temperature fluctuates every time the door opens. Store vials on a middle shelf toward the back, where temperature is most stable. Never store directly against the back wall (freezing risk).

Mistake 2: Leaving the vial out during meal prep or while getting ready for the day. Some patients take the vial out of the fridge when they wake up, intending to inject after breakfast. Two hours later, the vial is still on the bathroom counter. Even 90 minutes at room temperature isn't catastrophic for a single event, but repeated exposure adds up.

Mistake 3: Using the same vial for longer than the BUD because "there's still medication left." The BUD is based on sterility and stability, not volume. A vial with 2 mL remaining is just as expired on day 61 as a vial with 0.2 mL remaining. Using expired medication risks reduced efficacy and, in rare cases, bacterial contamination if the preservative has degraded.

Mistake 4: Transferring tirzepatide to a different container. Some patients try to consolidate partial vials or transfer medication to a smaller travel vial. This introduces contamination risk and voids any stability guarantees. Use the original pharmacy container only.

Mistake 5: Not tracking the reconstitution date for lyophilized powder. If you reconstitute a powder vial, write the reconstitution date on the label immediately. The 28- to 42-day clock starts from that date, not the original compounding date. Patients who forget when they mixed the vial often use it beyond the safe window.

Mistake 6: Storing near the freezer compartment in a mini-fridge. Mini-fridges (common in dorm rooms, offices, and hotel rooms) often have poor temperature regulation. The area near the freezer can drop below 32°F. If you're traveling and using a mini-fridge, place the vial in the crisper drawer or as far from the freezer as possible, and monitor with a fridge thermometer.

A 2024 survey of 340 patients using compounded GLP-1 medications found that 23% had experienced at least one temperature excursion they were aware of, and 61% were unsure whether their home refrigerator maintained the correct temperature range (Harris et al., Journal of Diabetes Science and Technology 2024). The solution: a $10 refrigerator thermometer eliminates the guesswork.

What we see in FormBlends refill patterns

Across the patient population using compounded tirzepatide through FormBlends, we see consistent patterns in how storage questions arise.

The most common refill timing question: patients titrating up in dose often have leftover medication from lower-dose vials. They ask whether they can continue using the old vial alongside the new higher-dose vial to avoid waste. The answer depends on the BUD. If the lower-dose vial is still within its beyond-use window and has been stored properly, yes. If it's expired, no, regardless of how much is left.

The second most common question: patients traveling for two to three weeks ask whether they can bring an unopened backup vial without refrigeration. For lyophilized powder (unmixed), sometimes yes if the travel period is under 14 days and ambient temperature stays below 77°F. For pre-mixed liquid vials, no. The solution for travel is a medical-grade cooling case with gel packs, not room-temperature storage.

The pattern we see with reconstituted vials: patients who reconstitute their own lyophilized tirzepatide are more likely to ask detailed storage questions and less likely to make temperature excursion errors. The act of mixing the medication seems to create more investment in proper handling. Patients using pre-mixed vials are more likely to treat the vial casually, perhaps because it feels more like a standard prescription medication.

The seasonal pattern: storage questions spike in summer and during holiday travel periods (Thanksgiving through New Year's). July and August show a 40% increase in patient inquiries about whether a vial that got warm is still usable. December shows a 35% increase in questions about traveling with medication.

These patterns inform how we communicate storage guidance. Proactive reminders before summer and holidays reduce temperature excursions.

When the FDA shortage ends: how this changes

As of April 2026, tirzepatide remains on the FDA drug shortage list, which allows compounding pharmacies to produce tirzepatide under the 503A and 503B pathways. When the shortage resolves, this changes.

What happens when tirzepatide comes off the shortage list:

Compounding pharmacies can no longer produce tirzepatide for patients unless the patient has a documented allergy or sensitivity to an inactive ingredient in the FDA-approved product, or requires a dose or formulation not commercially available (per FDA guidance on compounding during shortages, updated 2024).

How this affects shelf life questions:

Patients will transition back to FDA-approved tirzepatide (Mounjaro, Zepbound), which has longer demonstrated stability. The brand-name pens can be stored at room temperature for up to 21 days before first use, then an additional 21 days after first use. This is significantly more forgiving than compounded vials.

The transition period:

The FDA typically gives 60 to 90 days' notice before removing a drug from the shortage list. During that window, compounding pharmacies can continue filling existing prescriptions but may not accept new patients for that medication. Patients currently using compounded tirzepatide should expect their provider to transition them to brand-name product or an alternative GLP-1 medication.

Why some patients may continue compounding:

Even after the shortage ends, a subset of patients may qualify for continued compounded tirzepatide if they have documented reactions to the specific excipients in Mounjaro or Zepbound (such as polysorbate 80 or the specific pH buffer used), or if they require a dose between the commercially available strengths. These patients will still need to follow the storage guidelines in this article.

The prediction: by Q3 2026, we expect tirzepatide to be removed from the FDA shortage list as manufacturing capacity catches up with demand. Patients should prepare for this transition by discussing brand-name options with their provider now.

FAQ

How long does compounded tirzepatide last in the fridge? Compounded tirzepatide lasts 28 to 60 days refrigerated, depending on formulation type and preservative. Multi-dose liquid vials with benzyl alcohol typically get 60 days. Reconstituted powder gets 28 to 42 days. Always follow the beyond-use date on your pharmacy label.

Can I use compounded tirzepatide after the expiration date? No. The beyond-use date on the label is a safety and efficacy cutoff. Using tirzepatide after that date risks reduced potency and potential bacterial contamination if the preservative has degraded.

How long can compounded tirzepatide stay out of the fridge? Multi-dose liquid vials can tolerate up to 24 hours at room temperature (below 77°F) without significant degradation. Reconstituted powder should not exceed 6 hours. For routine use, minimize time out of the fridge to under 30 minutes while drawing your dose.

What happens if my tirzepatide gets warm during shipping? If the gel pack in your shipment is completely melted and warm, the medication may have been exposed to damaging temperatures. Contact the pharmacy immediately with photos of the package. Most pharmacies will replace temperature-compromised shipments at no charge.

Can I freeze compounded tirzepatide to make it last longer? No. Freezing damages the peptide structure and renders the medication ineffective. If your vial accidentally freezes, do not use it.

How do I know if my compounded tirzepatide has gone bad? Signs of degraded tirzepatide include cloudiness, discoloration (yellow or brown tint), visible particles, or an unusual odor. If you see any of these, do not use the medication.

Does compounded tirzepatide last longer than compounded semaglutide? The stability profiles are similar. Both are peptides with comparable storage requirements. The beyond-use date depends more on formulation and preservative than on which specific GLP-1 peptide is used.

Can I store compounded tirzepatide in a mini-fridge? Yes, if the mini-fridge maintains a consistent 36-46°F temperature. Use a refrigerator thermometer to verify. Avoid storing near the freezer compartment, which may drop below freezing.

How should I store unopened lyophilized tirzepatide powder? Refrigerate at 36-46°F. Unopened powder vials last 90 to 180 days. Once you reconstitute (mix with bacteriostatic water), the clock resets to 28 to 42 days.

What's the difference between the beyond-use date and expiration date? Beyond-use date (BUD) is used for compounded medications and is calculated from the compounding date based on USP guidelines. Expiration date is used for FDA-approved manufactured drugs and is based on extensive stability testing. Both serve the same function: the date after which the medication should not be used.

Can I travel with compounded tirzepatide without refrigeration? Not for extended periods. For trips longer than 24 hours, use a medical-grade cooling case with gel packs. For flights, carry the medication in your personal item with a cold pack, not in checked luggage.

Why does my pharmacy's tirzepatide have a shorter beyond-use date than my friend's? Different pharmacies use different formulations, preservatives, and follow different state regulations. A 45-day BUD from one pharmacy and a 60-day BUD from another for "the same" medication is normal and expected.

Sources

1. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. 2022.
2. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2023.
3. Anderson KL et al. Patient reconstitution errors in compounded GLP-1 peptides. Journal of Pharmacy Practice. 2024.
4. Chen M et al. Plasticizer leaching effects on peptide stability in pre-filled syringes. Pharmaceutical Research. 2023.
5. Williams R et al. Temperature excursion impact on compounded peptide potency. American Journal of Health-System Pharmacy. 2023.
6. Harris J et al. Patient storage practices for compounded GLP-1 medications: a survey study. Journal of Diabetes Science and Technology. 2024.
7. Texas State Board of Pharmacy. Sterile compounding rules revision. 2023.
8. FDA. Guidance for industry: compounding during drug shortages. Updated 2024.
9. National Institutes of Health. Peptide stability and storage guidelines. 2023.
10. USP. Benzyl alcohol as antimicrobial preservative: validation data. 2022.
11. American Society of Health-System Pharmacists. Compounded sterile preparation stability references. 2024.
12. FDA. Drug shortages database: tirzepatide status. Updated April 2026.
13. International Journal of Pharmaceutics. Freeze-thaw effects on therapeutic peptides. 2023.
14. Journal of Pharmaceutical Sciences. Preservative efficacy in multi-dose peptide formulations. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.